Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.

被引：0
|
作者：
Li, Regina
Mai, Helen
Chiasson, Kaitlyn
Trudeau, Maureen E.
Chan, Kelvin K.
Cheung, Matthew C.
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Canadian Agcy Drugs & Technol Hlth, Pan Canadian Oncol Drug Review, Toronto, ON, Canada
[3] CADTH, Ottawa, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[5] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14133
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada
    Li, Y. Y. R.
    Mai, H.
    Trudeau, M. E.
    Mittmann, N.
    Chiasson, K.
    Chan, K. K. W.
    Cheung, M. C.
    CURRENT ONCOLOGY, 2020, 27 (05) : E495 - E500
  • [2] REIMBURSEMENT RECOMMENDATIONS BASED ON PHASE II CLINICAL EVIDENCE FOR ONCOLOGY DRUGS IN CANADA
    Milenkovski, R. B.
    Yunger, S.
    Shum, D.
    VALUE IN HEALTH, 2016, 19 (03) : A163 - A163
  • [3] A comparison of public reimbursement for oncology versus non-oncology drugs in Canada.
    Bosnic, Nevzeta
    Donepudi, Krishna
    Goodfield, Jason
    Zhang, Yvonne
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Reimbursement Aproval of Oncology Drugs In Canada Supported By a Data Package Lacking Phase III Trial Data
    Macaulay, R.
    VALUE IN HEALTH, 2015, 18 (03) : A214 - A215
  • [5] Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea
    Bae, Green
    Bae, Eun Young
    Bae, SeungJin
    HEALTH POLICY, 2015, 119 (05) : 577 - 587
  • [6] Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada
    Meyers, Daniel E.
    Jenei, Kristina
    Chisamore, Timothy M.
    Gyawali, Bishal
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 499 - 508
  • [7] The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada
    Jean H. E. Yong
    Jaclyn Beca
    Jeffrey S. Hoch
    PharmacoEconomics, 2013, 31 : 229 - 236
  • [8] The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada
    Yong, Jean H. E.
    Beca, Jaclyn
    Hoch, Jeffrey S.
    PHARMACOECONOMICS, 2013, 31 (03) : 229 - 236
  • [9] Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
    Vreman, Rick A.
    Bouvy, Jacoline C.
    Bloem, Lourens T.
    Hovels, Anke M.
    Mantel-Teeuwisse, Aukje K.
    Leufkens, Hubert G. M.
    Goettsch, Wim G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (03) : 684 - 691
  • [10] USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND RISK OF PROSTATE CANCER IN MONTREAL, CANADA.
    Mansure, J. J.
    Franco, E. L.
    Ramanakumar, A. V.
    Aprikian, A. G.
    Kassouf, W.
    Parent, M. E.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S5 - S5
12345